Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 6/20 | 0.54 |
| ▸ | HTR2C | P28335 | 6/20 | 0.54 |
| ▸ | HTR2B | P41595 | 6/20 | 0.54 |
| ▸ | HRH3 | Q9Y5N1 | 5/20 | 0.54 |
| ▸ | SIGMAR1 | Q99720 | 8/20 | 0.46 |
| ▸ | PRCP | P42785 | 1/20 | 0.43 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.40 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7545824 | 0.98 | HTR2A (0.53) | HTR2AHTR2CHTR2BHRH3SIGMAR1 | |
| SCHEMBL352937 | 0.87 | SIGMAR1 (0.47) | HTR2AHTR2CHTR2BHRH3SIGMAR1 | |
| SCHEMBL22304223 | 0.83 | HTR2A (0.51) | HTR2AHTR2CHTR2BHRH3SIGMAR1 | |
| SCHEMBL2064332 | 0.82 | SIGMAR1 (0.56) | HTR2AHTR2CHTR2BHRH3SIGMAR1 | |
| SCHEMBL10785005 | 0.82 | SIGMAR1 (0.60) | HTR2AHTR2CHTR2BHRH3SIGMAR1 | |
| SCHEMBL11860825 | 0.81 | HTR2A (0.45) | HTR2AHTR2CHTR2BHRH3SIGMAR1 | |
| SCHEMBL21924071 | 0.80 | SIGMAR1 (0.63) | HTR2AHTR2CHTR2BHRH3SIGMAR1 | |
| SCHEMBL6542145 | 0.80 | SIGMAR1 (0.63) | HTR2AHTR2CHTR2BHRH3SIGMAR1 | |
| SCHEMBL4661810 | 0.80 | SIGMAR1 (0.63) | HTR2AHTR2CHTR2BHRH3SIGMAR1 | |
| SCHEMBL30285859 | 0.80 | SIGMAR1 (0.63) | HTR2AHTR2CHTR2BHRH3SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 116 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3729442-A1 | MOLECULE-BASED EQUATION ORIENTED REACTOR SIMULATION SYSTEM AND ITS MODEL REDUCTION | Aspen Technology, Inc. (US) | 2020-10-28 | — | — | EP | claimed |
| US-20190228843-A1 | Molecule-Based Equation Oriented Reactor Simulation System And Its Model Reduction | JPMORGAN CHASE BANK, N.A., AS ADMINISTRATIVE AGENT | 2019-07-25 | — | — | US | claimed |
| US-8148551-B2 | Tricyclic aromatics and liquid-crystalline medium | MERCK PATENT GESELLSCHAFT MIT BESCHRAENKTER HAFTUNG (DE) | 2012-04-03 | — | — | US | claimed |
| US-20080260630-A1 | Autothermal Hydrogen Storage and Delivery Systems | AIR PRODUCTS AND CHEMICALS, INC. (US) | 2008-10-23 | — | — | US | claimed |
| EP-0900228-B1 | A METHOD FOR PRODUCING OCTAHYDROFLUORENYL METAL COMPLEXES | DOW CHEMICAL CO (US) | 2002-06-12 | — | — | EP | claimed |
| EP-0900228-A1 | A METHOD FOR PRODUCING OCTAHYDROFLUORENYL METAL COMPLEXES | THE DOW CHEMICAL COMPANY (US) | 1999-03-10 | — | — | EP | claimed |
| WO-1997041134-A1 | A METHOD FOR PRODUCING OCTAHYDROFLUORENYL METAL COMPLEXES | THE DOW CHEMICAL COMPANY (US) | 1997-11-06 | — | — | WO | claimed |
| US-5670680-A | Method for producing octahydrofluorenyl metal complexes | THE DOW CHEMICAL COMPANY (US) | 1997-09-23 | — | — | US | claimed |
| CN-115197743-B | Method for preparing high-energy-density aviation fuel by regulating and controlling composition of hydrogenation stereoisomerism product of polycyclic aromatic hydrocarbon | 天津大学 | 2024-04-12 | — | — | CN | disclosed |
| CN-115197743-A | Method for preparing high-energy-density aviation fuel by regulating composition of polycyclic aromatic hydrocarbon hydrogenation stereoisomeric product | 天津大学 | 2022-10-18 | — | — | CN | disclosed |
| EP-3729442-A1 | MOLECULE-BASED EQUATION ORIENTED REACTOR SIMULATION SYSTEM AND ITS MODEL REDUCTION | Aspen Technology, Inc. (US) | 2020-10-28 | — | — | EP | disclosed |
| US-10610500-B2 | Chemosensory receptor ligand-based therapies | ANJI PHARMA (US) LLC (US) | 2020-04-07 | — | — | US | disclosed |
| US-20190228843-A1 | Molecule-Based Equation Oriented Reactor Simulation System And Its Model Reduction | JPMORGAN CHASE BANK, N.A., AS ADMINISTRATIVE AGENT | 2019-07-25 | — | — | US | disclosed |
| US-20190038576-A1 | Chemosensory Receptor Ligand-Based Therapies | ANJI PHARMACEUTICALS INC. | 2019-02-07 | — | — | US | disclosed |
| US-4347117-A | Donor solvent coal liquefaction with bottoms recycle at elevated pressure | EXXON RESEARCH & ENGINEERING CO. (US) | 1982-08-31 | — | — | US | disclosed |
| US-4332666-A | SOLVENT EXTRACTION | EXXON RESEARCH & ENGINEERING CO. (US) | 1982-06-01 | — | — | US | disclosed |
| EP-0051345-A2 | Donor solvent coal liquefaction with bottoms recycle at elevated pressure | EXXON RESEARCH AND ENGINEERING COMPANY (US) | 1982-05-12 | — | — | EP | disclosed |
| US-4311578-A | Liquefaction process wherein solvents derived from the material liquefied and containing increased concentrations of donor species are employed | EXXON RESEARCH & ENGINEERING CO. (US) | 1982-01-19 | — | — | US | disclosed |
| US-4081351-A | LIQUEFACTION, DISTILLATION, CATALYTIC CRACKING | MOBIL OIL CORPORATION (US) | 1978-03-28 | — | — | US | disclosed |
| US-3971804-A | ACARICIDES, FUNGICIDES, INSECTICIDES | BAYER AKTIENGESELLSCHAFT (DT) | 1976-07-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10610500-B2 | Chemosensory receptor ligand-based therapies | TAS1R2, TAS2R1, GPR119 | HTR2A 624/4885HTR2C 656/4885HTR2B 767/4885 |
| US-20190038576-A1 | Chemosensory Receptor Ligand-Based Therapies | TAS1R2, TAS2R1, GPR119 | HTR2A 624/4885HTR2C 656/4885HTR2B 767/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.